News | October 25, 2010

New Data Show Rosuvastatin Significantly Reduces Major Cardiac Events

October 25, 2010 - A post-hoc-analysis from JUPITER, published in the European Heart Journal, shows rosuvastatin (Crestor) significantly reduced major cardiovascular (CV) events, compared to placebo in high risk patients. The risk reductions observed in this patient population were consistent with those seen in the primary JUPITER analysis.

This analysis is based on subgroup data from the landmark JUPITER study, which studied men and women with low to normal LDL-C cholesterol levels but at increased cardiovascular risk as identified by age and elevated hsCRP.

"This newly published analysis of the JUPITER study reinforces the importance of rosuvastatin as an appropriate treatment option to reduce the risk of major cardiovascular events in high-risk patients as defined by the Framingham and SCORE risk factor assessment tools," said Michael Cressman, executive director of clinical research for Crestor. "Clinical studies have previously shown that rosuvastatin was the most effective statin at lowering LDL-C, had a significant effect on raising HDL-C and taken together with this analysis of JUPITER data, provides physicians with important information to help effectively reduce CV risk."

This analysis was the basis for the April approval of Crestor in 19 European Union countries for the prevention of major CV events in patients at high risk of having a first cardiovascular event.

In JUPITER, rosuvastatin 20 mg was well tolerated in nearly 9,000 patients.

Crestor has received regulatory approval in more than 100 countries.

For more information: www.astrazeneca.com

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Overlay Init